Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Clinical trial NCT05386550 · TERMINATED

Trial details

NCT number: NCT05386550
Sponsor: EMD Serono Research & Development Institute, Inc.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Head and Neck Cancer

Start date: 2022-10-06
Primary completion: 2024-08-27
Enrollment: 166

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.